PRNewsWire
23 May 2026, 13:43 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/gossamer-bio-inc-goss-faces-securities-class-action-amid-80-drop-on-phase-3-prosera-trial-failure-hbss-302780588.html
Read source
Search tags
Story key points
4 claims · impact-rated
Gossamer Bio's Phase 3 PROSERA study for seralutinib failed to meet its primary endpoint for treating pulmonary arterial hypertension. — The failure of a Phase 3 trial for a potential multi-billion-dollar lead candidate is a catastrophic loss of projected future revenue.
-1.00Gossamer Bio's share price dropped 80% following the announcement of the trial failure. — A massive price collapse indicates a severe loss of market confidence and a wipeout of most shareholder value.
-0.80Gossamer Bio has failed to meet the minimum $1 share bid price required for continued listing on the Nasdaq Global Select Market. — Potential delisting increases liquidity risk and often triggers further selling pressure.
-0.70A securities class action lawsuit has been filed alleging Gossamer misled investors regarding PROSERA trial design and patient recruitment. — Legal liabilities and potential settlements create additional financial headwinds and management distraction.
-0.50Impact vectors
6 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company faces a securities class action lawsuit following a Phase 3 trial failure and an 80% drop in stock price.
Mentioned positively in the context of a highly successful Phase 3 study of sotatercept.
